Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia.

ABSTRACT:

Objective

Preterm infants are at a high risk of developing BPD. Although progression in neonatal care has improved, BPD still causes significant morbidity and mortality, which can be attributed to the limited therapeutic choices for BPD. This review discusses the potential of MSC in treating BPD as well as their hurdles and possible solutions.

Data sources

The search for data was not limited to any sites but was mostly performed on all clinical trials available in ClinicalTrials.gov as well as on PubMed by applying the following keywords: lung injury, preterm, inflammation, neonatal, bronchopulmonary dysplasia and mesenchymal stem cells.

Study selections

The articles chosen for this review were collectively determined to be relevant and appropriate in discussing MSC n

SUBMITTER: Tang E 

PROVIDER: S-EPMC9527154 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature